Research Analysts Set Expectations for Actinium Pharmaceuticals, Inc.’s FY2024 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 30th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings of ($1.35) per share for the year, up from their prior estimate of ($1.84). Cantor Fitzgerald currently has a “Overweight” rating and a $21.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.59) per share.

ATNM has been the topic of a number of other reports. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, April 29th. Finally, StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 29th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Stock Up 1.8 %

Actinium Pharmaceuticals stock opened at $8.91 on Thursday. The firm has a market cap of $265.34 million, a price-to-earnings ratio of -5.21 and a beta of 0.08. Actinium Pharmaceuticals has a twelve month low of $4.00 and a twelve month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently modified their holdings of ATNM. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 1st quarter worth about $78,000. Creative Financial Designs Inc. ADV boosted its stake in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter worth about $1,033,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.